Navigation Links
Stereotaxis to Present at the JMP Securities Healthcare Conference
Date:9/24/2010

ST. LOUIS, Sept. 24 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today announced that executive management will present at The Fifth Annual JMP Securities Healthcare Conference on Tuesday, September 28, 2010 at 8:30 a.m. ET in New York. Dan Johnston, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only. A live audio and slides webcast of Stereotaxis' presentation may be accessed through the Company's website at http://www.stereotaxis.com/Investor-Relations. The replay will be available for 90 days.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The unparalleled clinical capability of Stereotaxis has driven more than 130 hospitals to adopt magnetic navigation for a growing number of complex ablation cases in all four chambers of the heart. Stereotaxis technology is now installed and used by 9 out of the Top 10 Best U.S. Heart Hospitals as ranked by U.S. News and World Report, and more than one third of the EP academic training centers in the United States have included Stereotaxis into their arrhythmia treatment laboratories. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

About Odyssey

The Odyssey portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information around the world. Odyssey Vision standardizes data integration for magnetic and standard interventional labs by enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Through its proprietary data compression technology, Cinema enables sharing of live and recorded procedure data via a laptop anywhere over a secure high speed Internet connection. Hospitals can also share procedures with other institutions using Odyssey Network Connect providing a global forum for defining clinical best practices across a broad spectrum of medical procedures.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent
2. Stereotaxis to Present at the CL King Best Ideas Conference and the Stifel Nicolaus Healthcare Conference
3. Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
4. Stereotaxis Announces Second Quarter 2010 Earnings Release Date and Conference Call
5. New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects
6. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
7. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
8. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
9. Stereotaxis Installs First System in Taiwan
10. Stereotaxis System Procedure Featured on NBCs The TODAY Show
11. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Non-invasive diagnostic test realizes the potential ... to be presented at Yissum’s booth, at IATI-BIOMED 2016 ... of the Hebrew University of Jerusalem announced today ... Ventures MKI, the technology investment arm of Morris Kahn ... for early detection of multiple diseases by analyzing circulating ...
(Date:5/22/2016)... May 23, 2016 DS ... anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive ... non-alcoholic steatohepatitis (NASH) patients. Recent DS ... in lung tissue and has bronchodilatory, anti-inflammatory and ... administration. The Company will publish further detail on ...
(Date:5/20/2016)... , May 20, 2016 ... Pipeline Review, H1 2016" market research report with ... Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... American Spine in ... invasive, endoscopic spine surgeries in the Montgomery County, Howard County and Washington, D.C. ... Germantown office of American Spine every Monday. He will also perform surgeries in ...
(Date:5/24/2016)... ... 24, 2016 , ... PhishLine, the best-in-class, enterprise level security ... Vice President of Sales. Cifolelli’s primary responsibilities include management of the company’s ... expanding field of organizational social engineering. , “We are delighted to have ...
(Date:5/24/2016)... ... 24, 2016 , ... i2i, a national leader in population ... “Transforming Outcomes” User Conference in Las Vegas on May 19-20, 2016. The ... the market standard for meaningful population health management. The company recently closed ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and to housing, with more advantaged communities providing richer opportunities. Recognizing the key ... interventions: (a) school improvement policies; (b) school choice policies; (c) school desegregation policies; ...
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens ... of Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its protest against ... Industry of Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s ...
Breaking Medicine News(10 mins):